<DOC>
	<DOCNO>NCT01280955</DOCNO>
	<brief_summary>This phase I/II clinical trial test safety efficacy post transplant administration plerixafor enhance hematological recovery human . Patients appropriate candidate myeloablative allogeneic stem cell transplantation HLA-matched sibling , match unrelated donor umbilical cord blood eligible enrollment . The investigator plan enroll total 50 patient study ( 30 patient HLA-matched sibling match unrelated donor transplant , 20 patient umbilical cord blood transplant ) . During phase I study , small number patient ( 3-6 patient group ) enrol determine safety post transplant administration plerixafor . Patients receive plerixafor give 240 Âµg/kg subcutaneously every day begin day +2 transplant day +21 engraftment . Limiting toxicity define primary secondary graft failure , plerixafor-related severe premature ventricular arrhythmia death . If safety criterion meet investigator phase I study , investigator proceed phase II study determine efficacy post transplant administration plerixafor enhance haematological recovery . The experimental aspect study use plerixafor aspect care line standard care . Both Phase I Phase II patient combine efficacy analysis , data collect study compare investigator historical control . The result study set stage provide justification large phase 3 trial .</brief_summary>
	<brief_title>Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant</brief_title>
	<detailed_description>Recruitment trial stratify donor type HLA ( human leukocyte antigen ) match sibling , match unrelated donor umbilical cord blood . Patients condition myeloablative regimen , limit , total body irradiation cyclophosphamide . The donor stem cell graft come mobilize peripheral blood 8/8 7/8 HLA-identical family member , 8/8 ( HLA A , B , C , DRBeta1 ) allele-level match unrelated donor , dual umbilical cord blood graft least 4 6 HLA match HLA A B ( low resolution ) DRBeta1 ( high resolution ) . The target CD34+ cell dose 5 X 10 ( 6 ) /kg recipient ideal body weight . For HLA match sibling match unrelated donor ( MUD ) transplant , patient receive minimum 2 X 10 ( 6 ) CD 24+ cells/kg . For cord blood transplant , unit contain minimum total nucleate cell count 1.5 X 10 ( 7 ) /kg . Post-transplant GVHD ( graft versus host disease ) prophylaxis give per institutional standard .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Age 18 65 year . 8/8 7/8 HLAidentical match sibling OR Allele level 8/8 ( HLAA , B , C , DR Beta1 ) match unrelated donor 4/6 good HLA match cord blood . Patients high risk hematologic malignancy appropriate candidate myeloablative allogeneic stem cell transplantation . Patients history CNS disease must treat active CNS disease time protocol treatment . ECOG performance status &lt; equal 2 Patients must adequate function organ system measure : Creatinine clearance ( Cockcroft Gault equation ) &gt; equal 30ml/min . Hepatic transaminase ( ALT/AST ) &lt; equal 4 x normal , bilirubin &lt; equal 2.0 mg/dl . Pulmonary function test demonstrate FVC FEV1 &gt; equal 50 % predict age DLCO &gt; equal 50 % predict . Ejection fraction &gt; equal 45 % echocardiogram , radionuclide scan cardiac MRI . Patients must HIV negative . Patients must pregnant . Patients &gt; 5 % blast bone marrow peripheral circulation . Uncontrolled infection . Class III IV angina per NYHA criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Plerixafor Allogeneic Myeloablative Stem Cell Transplant</keyword>
</DOC>